Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From John Davis
Sanofi will have €1.9bn to add to its war-chest when it concludes the sale of its European generics business.
OlympiAD data update backs AZ/Merck & Co.'s PARP inhibitor in metastatic breast cancer, but study not powered to give definitive answer about its effects on overall survival.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Sanofi's major investments in vaccine manufacturing are continuing with the expansion of its Toronto, Canada facility, to be completed in 2021.
An interim analysis has recommended stopping the Phase III ATLAS study because axitinib was failing to show it extended disease-free survival when used as adjuvant therapy in earlier-stage renal cell carcinoma patients. However, combination studies of axitinib with immuno-oncology agents will continue.
Respiratory delivery specialist Vectura is to concentrate on developing enhanced inhaled products, as well as substitutable inhaled generics for the US market, and is pulling back from NME work. CEO James Ward-Lilley explains why.